Coillancarraig Lodge, Rocky Valley Drive, Kilmacanogue, Co Wicklow, Ireland
*Corresponding author:Gerald H Tomkin, Coillancoraig Lodge, Rocky valley Drive, Kilmacanogue, Ireland
Submission: March 12, 2019Published: June 20, 2019
ISSN : 2578-0263Volume3 Issue1
Obesity is commonly associated with type 2 diabetes. Weight reduction in obese subjects is effective in both preventing the onset of type 2 diabetes and in reversing the condition once present. GLP1 agonists have been shown to inhibit appetite both by delaying gastric emptying and increasing saiety at a central level. These drugs have been shown to delay the onset of type 2 diabetes, to reverse diabetes and to lower blood sugar in patients with Type 2 diabetes. Development of these drugs has resulted in prolongation of absorption so that they may be given by subcutaneous injections and more recently reports of an oral preparation of semaglutide that has similar efficacy to the subcutaneous preparation have appeared. The drugs have been shown to result in cardiovascular protection.
Keywords: Diabetes; Extendin 1,2,3,4; GLP-1 Receptor; DPP-4; Oral Semaglutide; Obesity
Abbreviations: VIP: Vasoactive Intestinal Peptide